Objective. Anti-citrullinated protein antibodies (ACPAs) develop many years before the clinical onset of rheumatoid arthritis (RA). This study was undertaken to address the molecular basis of the specificity and cross-reactivity of ACPAs from patients with RA.
INTRODUCTION
A hallmark of autoimmune diseases is the production of autoantibodies. There has been a revival of interest in furthering understanding of their functional roles, since these autoantibodies precede the clinical onset in most autoimmune diseases. However, knowledge of their exact interactions with target epitopes is very limited. Rheumatoid arthritis (RA) is one of the most prevalent autoimmune diseases, affecting ~0.5% of the world population. The occurrence of rheumatoid factors (RFs), i.e., antibodies selfreactive with the Fc portion of IgG, and autoantibodies against citrullinated proteins (ACPAs) have been found to be specific for RA, and both have been suggested to take part in disease development (1) (2) (3) (4) . RFs and ACPAs appear years before the clinical onset of RA (5, 6) , and both are included in the American College of Rheumatology (ACR)/European League Against Rheumatism 2010 classification criteria for RA (7) .
ACPAs are typically detected by commercial enzyme-linked immunosorbent assay using a certain set of undisclosed cyclic citrullinated peptides (CCPs), specifically CCP-2. Up to 70% of RA patients are found to be anti-CCP-2 positive, and the occurrence of ACPAs is linked to poorer prognoses (8) .
A variety of citrullinated autoantigens have been characterized and suggested to be potential ACPA targets, such as α-enolase, | 211 fibrinogen, filaggrin, vimentin, and type II collagen (CII) (9) (10) (11) (12) (13) . Some ACPAs may have a more antigen-specific reactivity to certain citrullinated proteins, but most seem to be widely cross-reactive (14) .
It is believed that both RFs and ACPAs promote the formation of immune complexes, but their pathogenic roles in vivo remain unclear. Several lines of evidence have indicated that ACPAs may play a critical role in the pathogenesis of RA. ACPAs have been reported to activate osteoclasts, to trigger bone erosions via an interleukin-8 (IL-8)-dependent pathway, and to elicit joint pain when injected into mice (15) (16) (17) . ACPAs are also capable of inducing the secretion of tumor necrosis factor from macrophages through Fcγ receptor engagement, and of mediating complement activation via both the classical and alternative pathways (18) . However, it is still unclear whether the demonstrated pathogenic effects of ACPAs are specifically related to their citrulline specificity or whether they could be attributed to other intrinsic characteristics, such as Fc glycosylation (19, 20) .
So far, only a subtype of ACPAs cross-reactive with joint cartilage has been shown to be able to induce arthritis upon direct injection into mice (21, 22) . Interestingly, Fc glycan sialylation of these antibodies transforms them into protective antibodies (19) . Most ACPA-positive sera from RA patients are cross-reactive with several different citrullinated peptides (14) . However, the molecular interactions of ACPAs with their citrullinated epitopes, clarification of which could explain both their wide cross-reactivity and their specificity for citrulline, are poorly understood.
To address this question, we produced several human monoclonal ACPAs and characterized their binding properties. In this study, we characterized, for the first time, the crystal structures of the Fab fragment of 1 of these ACPAs in complex with 3 sequenceunrelated peptide epitopes. Our results showed that at least some ACPAs specifically recognize the citrulline residue in a manner largely independent of the peptide epitope sequences. This finding has general importance, since the autoantibody responses to 3 citrullinated antigens, which were bound by the monoclonal ACPA Fab fragment in the crystal complexes, reached high titers and were found to be present at a high frequency in the serum of patients in 2 well-characterized Swedish RA cohorts.
PATIENTS AND METHODS
Patient population. In the present study, serum samples from 2 cohorts of RA patients were used for assessment of antibody reactivity by Luminex immunoassay. First, a part of the cohort of the second Swedish Early Intervention in RA trial (TIRA-2) (23) was used (n = 504), and as controls, we used healthy subjects from the cohort of the Western Region Initiative to Gather Information on Atherosclerosis (n = 285). The study protocol was approved by the regional ethics review board in Linkköping, Sweden.
Second, a subset of RA patients in the previously described Swedish Epidemiological Investigation of RA (EIRA) cohort (24) was used (n = 575), and 191 healthy subjects were used as controls. RA in the patients in the EIRA cohort was diagnosed according to the ACR 1987 classification criteria (25) . The study was approved by the Karolinska Institutet ethics review board. For additional information on the study subjects and methods used, see Supplementary Patients and Methods (available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40698/abstract).
Suspension bead array.
In the serum samples obtained from RA patients, autoantibody responses were analyzed by Luminex immunoassay, as described previously (26) . The median fluorescence intensity (MFI) was used to quantify the interaction of serum antibody with the given peptides.
Expression and purification of chimeric antibodies.
The corresponding DNA fragments for the given antibodies were cloned into the vector pCEP4 (Life Technologies), and then the plasmids were cotransfected into Expi293F cells (Life Technologies) with FectoPRO DNA transfection reagent (Polyplus transfection). The chimeric antibody was purified using a 5-ml HiTrap Protein G HP affinity column (GE Healthcare Life Sciences) according to the manufacturer's instructions.
Preparation and purification of the chimeric E4 Fab fragment. The E4 Fab fragment was prepared using an ImmunoPure Fab Preparation Kit (Pierce) in accordance with the manufacturer's instructions. The Fab fragments for D10 and B10 were produced as described previously (27) .* The Fab fragments used for crystallization were further purified by size-exclusion chromatography using a HiLoad 16/600 Superdex 200 column.
Crystallization, data collection, and structure determination. For the complexes, the Fab fragments in 20 mM Tris (pH 7.4)-20 mM NaCl were mixed with the cognate peptides in 2-3 times molar excess, before crystallization. Diffraction data were collected at the beamlines (specific data are provided in Supplementary Table 3 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/art.40698/ abstract). The images were processed using XIA2 (28) (29) (30) , and scaled using the Aimless application (31) from the Collaborative Computational Project 4 (CCP4) program suite (32) .
The structure of the E4 Fab -CII-C-13 complex was determined by molecular replacement using Phaser crystallographic software (33) . Iterative cycles of the manual model building were carried out using the Coot crystallographic object-oriented molecular graphics toolkit (34) Statistical analysis. The nonparametric Wilcoxon's rank sum test was applied for analysis of differences in MFI ratio values between RA patients and healthy controls. Reactivity of a peptide was considered positive if the MFI ratio was above a predefined MFI ratio threshold, defined as the median plus 5 times the median absolute deviation of that obtained in healthy control serum. All calculations were done in R software using several packages (40) . For comparison, we also analyzed 2 other previously reported monoclonal ACPAs, designated D10 and B2. They were originally generated from joint-derived B cells of RA patients and were reported to bind to citrullinated peptides derived from α-enolase (CEP-1), fibrinogen, and vimentin (27) . They were produced in the same mouse IgG2b-based chimeric format. In addition, we analyzed 2 ACPAs (ACC1 and ACC4) that were generated from mouse serum. These have been shown to be arthritogenic, based on findings of their cross-reactivity with triple helical CII (ACC1) or with a citrullinated peptide derived from CII (ACC4) (21, 22) .
RESULTS

Generation
To comprehensively map the breadth of reactivity of chimeric E4 and F3, a large set of 17-mer cyclic CII-derived arginine-containing peptides and the corresponding citrulline-containing peptides were synthesized (see Supplementary Table 2 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/doi/10.1002/ art.40698/abstract) and examined by Luminex immunoassay. Commonly used citrullinated peptides derived from α-enolase (CEP-1), fibrinogen, vimentin, and filaggrin (CCP-1) were also included (43) . A remarkable difference in reactivity was observed between the citrullinated peptides and the respective arginine-containing peptides ( Figure 1A ). Neither E4 nor F3 showed reactivity toward any argininecontaining peptides. However, both E4 and F3 recognized several citrullinated CII peptides (CII-C-13, CII-C-23, CII-C-38, CII-C-39, and CII-C-48) and CEP-1. The CII peptides CII-C-17, CII-C-27, CII-C-29, CII-C-49, and CII-C-54 and the Vim 58-77 peptide were only recognized by E4, while the peptides CCP-1, Vim [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] , and CII-C-51 were solely recognized by F3, suggesting that there are qualitative differences in cross-reactivity between E4 and F3. Notably, all of the CII-derived peptides recognized by both ACPAs contained a conserved Cit-Gly motif in their sequences. In addition, both the WT and NG forms of E4 and F3 showed subtle differences of binding strength/affinity against the same peptide. This is consistent with our previous observation that variable-domain glycosylation was able to modify the binding avidity to citrullinated antigens (42) . In contrast, we did not observe binding of the other 2 monoclonal ACPAs (D10 and B2) to any constituent of the present peptide library (data not shown).
Furthermore, we measured the affinity of both E4 and F3 for CEP-1 by surface plasma resonance (SPR) imaging, using the corresponding arginine control peptide as a reference. Our findings revealed that E4 had a stronger affinity/avidity for CEP-1 (measured by the dissociation constant [K d M for B2 Fab ) in our SPR assay in which an empty reference channel was used, but the specificity for CEP-1 was totally abrogated when the arginine-containing control peptide was used as the reference channel (results in Supplementary Figure 2 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40698/abstract), thus showing that neither D10 nor B2 is a citrulline-specific antibody.
In summary, compared to F3, E4 showed a broader range of reactivity toward citrullinated CII peptides, but the N-glycan in the antibody combining site did not affect its specificity. Thus, the nonglycosylated forms of E4 (E4NG) and F3 (F3NG) were chosen for more detailed analyses in the present study.
Overall structure of the E4 Fab and complex forms.
To identify the structural determinants of citrulline specificity and epitope cross-reactivity of the ACPAs, we determined the crystal structures of the E4 Fab fragment complexed with 3 distinct citrullinated peptides (CII-C-13, CII-C-48, and CEP-1) selected from onlinelibrary.wiley.com/doi/10.1002/art.40698/abstract). In 3 complex structures, the E4 Fab adopted a characteristic Ig fold with clearly defined electron density. Peptides CII-C-13 and CII-C-48 were also well defined by electron density in the complexes, except for their terminal parts, which extended beyond the binding site. The entire CEP-1 peptide was clearly seen in the complex structure ( Figure 2B ). The Fab fragment in the complexes with CII-C-13 and CEP-1 contained the murine IgG2a constant region, whereas the E4 Fab fragment present in the crystals in the unbound state and in complex with CII-C-48 contained the murine IgG2b constant region.
Due to the differences in the constant region and/or the crystal lattice, the relative orientations of the variable and constant domains of the single E4 Fab in these crystals (211° and 218° per asymmetric unit, respectively) deviated significantly from those observed for the E4 Fab in the complexes with CII-C-13 and CEP-1 (149-150° per asymmetric unit) (results in Supplementary Figures  3A and B narrow grooves that were connected at both ends, and in the middle it was separated by a ridge formed by H-G102 and H-S103 from CDR H3 and L-F33 of CDR L1, thus giving it an overall ring-or zero-like shape ( Figure 3A) . At one end of the "zero," the groove had a distinctly negative electrostatic potential, whereas the dominating features at the other end were an ~8Å deep pocket formed by H2 (H-W48, H-S51, H-Y59), H3 (H-I99, H-N105), and L3 (L-F99) residues, flanked by a hydrophobic patch and a patch of positive electrostatic potential ( Figures 3A and B) .
All 3 distinct peptide epitopes adopted a bent conformation to match the groove (Figure 2 and Supplementary Figure 3 [http://onlinelibrary.wiley.com/doi/10.1002/art.40698/abstract]). However, they showed identical conformations for the signature 
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Cit-Gly motif and the directly following residue, as well as the 3 preceding amino acids, with the long citrulline side chain being inserted into the deep pocket.
Superimposition of the variable domains of the E4 Fab -peptide complex revealed that the conformation of the CDR loops was almost identical, despite their binding to different peptide sequences ( Figure 3C ; see also Supplementary Table 5 the E4 Fab -CEP-1 complex ( Figure 3D ). Superimposition with the corresponding peptide-free structure revealed that the paratope was stably preformed in the absence of antigen, since peptide binding induced few and very modest changes in the CDR residue conformations ( Figure 3E ).
Citrulline recognition was largely mediated by formation of 3 hydrogen bonds to its side chain ( Figure 3B ), namely 1) between the oxygen atom of the ureido moiety and the hydroxyl group of H-S51, as well as the amine nitrogen of H-W48, and 2) between 1 of the ureido group nitrogen atoms and the carboxamide oxygen of H-N105. Since this deep pocket is nonpolar, insertion of a charged side chain should be energetically disfavored, thereby explaining the strict selectivity for citrulline epitopes as compared to arginine-containing epitopes.
Furthermore, 3 direct and 2 water-mediated hydrogen bonds were found to be conserved in all 3 E4 Fab -peptide com- Table 5 [http://onlinelibrary.wiley.com/ doi/10.1002/art.40698/abstract]). The citrulline interacted with the hydroxyl group of H-Y59, the Cit-Gly motif glycine, and the peptide residue preceding the citrulline, p(Cit-1). In addition, the citrulline interacted with both the backbone oxygen and nitrogen of H-G102, and the p(Cit-3) residue made water-mediated contacts to the backbone groups of both H-S32 and H-G101.
Several additional polar contacts were also observed, namely the hydrogen bonding of the Cit-Gly motif glycine to the carboxamide group of H-N105 (direct) and to the backbone oxygen of H-S103 (water-mediated) that was observed in the E4 Fab complexes with CII-C-13 and CII-C-48, and the water-mediated hydrogen bonds between the p(Cit-2) and the hydroxyl groups of H-T55 and H-T57 that were observed in the CII-C-13 and CEP-1 complexes.
All of these polar interactions engaged peptide main-chain atoms. Therefore, they were not epitope sequence-specific, giving rise to the strong cross-reactivity of E4.
Based on our characterization of the 3 analyzed epitopes, CEP-1 binding showed several characteristic features not shared by the 2 CII-derived peptides. The entire CEP-1 sequence, except for pE7 and pI8, was well defined in electron density ( Figure 2B ). Both ends of the CEP-1 peptide were closely associated via 3 intrapeptide hydrogen bonds as well as a disulfide bridge ( , respectively, for the complex with CII-C-48). For CII-C-13 and CII-C-48, the electron density was observed only for residues 4-13 and 5-13, respectively ( Figure 2B) , with both N-and C-termini exiting the E4 Fab paratope earlier than the corresponding CEP-1 residue. This could be attributed to differences in peptidebinding modes rather than to differences in crystal packing.
Both CII-C-13 and CII-C-48 contained a hydrophobic residue, a positively charged residue, and a glycine directly following the Cit-Gly motif (Figures 4B and C and Supplementary Figure  4 [http://onlinelibrary.wiley.com/doi/10.1002/art.40698/abstract]). The side chain of the hydrophobic residue (for CII-C-13, pA11; for CII-C-48, pL11) was inserted in a relatively nonpolar side extension of the main peptide-binding groove, whereas the long positively charged arginine (for CII-C-13) and lysine side chains (for CII-C-48) interacted with an area of negative electrostatic potential of the main groove, thus causing the exit of the p(Cit+4) glycine and all residues following from it. The positively charged p(Cit+3) side chains were hydrogen-bonded to the carboxyl group of L-D52 and the backbone oxygen of L-A32 in both the E4 Fab -CII-C-48 and E4 Fab -CII-C-13 complexes, although directly in the former and water-mediated in the latter.
The interactions between the E4 paratope and peptide antigen were dominated by the above-described polar contacts, as relatively few short-distance (<3.8Å) hydrophobic contacts were observed in all 3 complexes (Supplementary Table 5 [http:// onlinelibrary.wiley.com/doi/10.1002/art.40698/abstract]). The primarily polar nature of the E4 paratope, providing numerous hydrogen bond donor and acceptor groups, was further highlighted by the observation of 3 glycerol molecules originating from the crystallization/cryoprotection solution in the peptide-binding groove of the antigen-free E4 Fab crystal structure ( Figure 4D and Supplementary Table 5 ).
Structural comparisons with other ACPAs. The crystal structures of 2 murine ACPAs, ACC1 (PDB accession code 5mu0) and ACC4 (PDB accession code 2w65) in complex with citrullinated peptides, have been reported previously (21, 22) . ACC1 is a highly arthritogenic antibody that targets the citrullinated C1 epitope on CII but also cross-reacts with several noncitrullinated epitopes on native CII, as well as with some classic citrullinated peptides such as CCP-2 and CCP-1. ACC4 is, on the other hand, specific for the citrullinated CII-C1 epitope in the non-native, single α-chain form. Interestingly, it enhanced arthritis severity when given concomitantly with another CII-specific antibody, M2139 (22) . We also determined the crystal structures of the human antibodies B2 and D10, which were the first to be cloned from human RA serum and were reported to be specific for citrulline but cross-reactive with several citrullinated peptides (27) . Both B2 and D10 were cocrystallized with full-length or truncated versions of CEP-1, but no electron density attributable to bound peptides was observed (Supplementary Figure 5) . Furthermore, neither of them showed detectable affinity for a library of more than 150 citrullinated peptides in the binding assay. We could therefore conclude that these are not ACPAs.
Superimposition of the E4 Fab , ACC1 Fab , ACC4 Fab , B2 Fab , and D10 Fab structures revealed significant differences in the size, shape, and properties of their paratopes. The ACC1 paratope is set apart from the others by being located in a deep, openended cleft between the heavy-and light-chain CDR that enables it to bind to a single α-chain of the CII epitope, most likely bulging out of a rigid triple-helical collagen structure (21) (Figures 5A-E) . Citrulline-versus-arginine specificity is most likely imposed by the electrostatic properties of a nearby surface patch. In contrast, the ACC4 paratope is located in a smaller, enclosed groove, and the citrulline specificity is mediated by a network of hydrogen bonds to the ureido moiety.
Since the peptide specificities of B2 Fab and D10 Fab are unknown, the features of their peptide recognition could not be determined explicitly from the current forms of their unbound crystal structures. Notably, we did not observe a structurally similar binding pocket for an accommodating citrulline side chain in the paratopes of both B2 Fab and D10 Fab as that observed in the E4. This implies that they lack the structural determinants of specificity for citrulline.
In summary, based on the crystal structures of the ACPAs in complex with citrullinated epitopes, we can conclude that citrulline specificity may be achieved in a manner that varies slightly, either by providing both a hydrogen-bonding partner group pattern selective for citrulline and electrostatic surface properties that bias against arginine, or by providing just the latter feature. However, no conserved feature regarding the shape of the citrulline-binding pocket can be expected.
Autoantibodies against E4-bound citrullinated peptides in RA.
To evaluate the prevalence of the E4-bound citrullinated peptides in RA patients, we selected as potential targets the 3 representative citrullinated peptides that had been found to cocrystallize with E4, and used a Luminex immunoassay to measure their autoantibody levels in 2 large cohorts of RA patients (the EIRA and TIRA-2 cohorts). In both cohorts, a statistically significant difference in antibody responses was clearly seen between healthy controls and RA patients, with regard to reactivity toward CEP-1, CII-C-13, and CII-C-48 (Figures 6A  and B and Supplementary Table 6 , available on the Arthritis & Rheumatology web site at http://onlinelibrary.wiley.com/ doi/10.1002/art.40698/abstract). In ~46% of the RA patients in the EIRA cohort (and 51% of RA patients in TIRA-2), a response to citrullinated CII-C-13 was seen, which was comparable to the frequency of reactivity toward citrullinated CII-C-48 (40% of RA patients in EIRA, and 44% of RA patients in TIRA-2). The sen- sitivity for CEP-1 was higher than that for the 2 citrullinated CII peptides in both cohorts (68% of RA patients in EIRA, and 61% of RA patients in TIRA-2). In addition, in the serum from ~40% of RA patients in both cohorts, reactivity against all 3 citrullinated peptides was seen ( Figure 6C ), suggesting that a significant proportion of antibodies in patients with RA show a high degree of cross-reactivity.
DISCUSSION
We provide herein the first molecular characterization of the interactions between a human-derived ACPA and several citrullinated peptides, revealing the structural basis of the citrulline specificity and cross-reactivity of ACPAs, and explaining how both a promiscuous binding of citrullinated epitopes and a very high specificity of the citrulline side chain can be combined.
The crystal structures of the E4 ACPA bound to citrullinated peptides revealed conserved interactions with the citrulline residue. The citrulline is deeply inserted into a narrow pocket of the E4 Fab paratope, where it is specifically recognized by the formation of 3 hydrogen bonds to its side chain. The nonpolar character of this pocket biases against recognition of corresponding positively charged arginine. Almost all of the hydrogen-bonding interactions between the remaining epitope residues and the antibody CDR loops engaged peptide main-chain groups, allowing for extensive cross-reactivity.
Several studies showed that ACPA responses are highly cross-reactive toward citrullinated antigens, regardless of their origins (14, 41, 44, 45) . Consistent with these observations, the Luminex screening assay using a library of CCPs derived from CII and classic citrullinated peptides clearly showed that both E4 and F3 could recognize several peptides whose sequences were distinct except for the presence of a citrulline, strong preference for a glycine as the (Cit+1) residue, and the high frequency of Gly-X-Y repeats natively occurring in CII. Thus, the flanking residues of citrulline, in conjunction with specific recognition of the citrulline side chain, are most likely the determining factors in the reactivity of these ACPAs, rather than being attributable to a dependence on conserved amino acid sequence features.
The structures of E4 Fab in both its antigen-free and peptidebound forms provide valuable insights into the molecular mechanisms of antigen recognition. Peptide binding induced only minor changes in the E4 paratope structure, which is largely preformed and relatively static. Thus, the significant cross-reactivity of E4 with epitopes that are very diverse in sequence appears not to be dependent on the flexibility/adjustability of the CDR loop conformation. By comparing the conformation of the 3 peptides bound to E4 in the crystals with their native forms (i.e., CII and α-enolase), we found that they indeed undergo substantial conformational rearrangements upon binding to E4. The fact that the peptide conformation is essential for autoantibody reactivity is a finding that has been observed previously (44, 46, 47) .
E4 engages a key region (i.e., the 2-3 amino acids flanking the central citrulline residue on both sides) of the peptide that predominantly determines specificity but leaves the distal positions open to more diversity. Importantly, the primarily polar interactions involving peptide main-chain atoms could be identified as the major determinant of the cross-recognition of diverse citrullinated peptides by E4. Nevertheless, E4 or F3 still bound only to a subset of citrullinated peptides in our Luminex immunoassay. This indicates that the other physical characteristics of the peptide, such as neighboring residues flanking the citrulline, could influence the ACPA recognition that was previously investigated (48) .
Characterization of the crystal structures of the E4 Fab -peptide complexes confirmed that the Cit-Gly motif is essential for recognition. It was reported that only the peptides containing the CitGly motif showed significant antibody reactivity in the serum of RA patients, and that the substitution of glycine with residues harboring small side chains could reduce antibody reactivity (44, 45, 48) . The preference for glycine at the (Cit+1) position is due to the steric hindrance imposed by the antibody residues at this position. In addition, the less spatial restriction due to the lack of a side chain allows glycine to occur frequently in the turn region of the polypeptide chain, which was seen for all 3 peptides in the crystal structures.
The same citrullinated peptides (CII-C-13, CII-C-48, and CEP-1) bound by monoclonal E4 in crystal complexes were also recognized by high titers of antibodies in 2 large well-characterized RA cohorts, thus confirming the clinical relevance of these peptides. As shown in Figure 6C , in the majority of RA patients, antibody reactivity to all 3 peptides was seen, suggesting that E4-like ACPAs are frequent in these patients. Notably, preferable binding to one particular peptide was seen in the RA serum, suggesting that nonoverlapping ACPAs are present. More importantly, the extensive intramolecular hydrogen bond formed by CEP-1, maintaining an overall favorable conformation for ACPA binding, leads to a higher sensitivity of CEP-1 compared to that of CII-C-13 and CII-C-48, both of which lack an intramolecular hydrogen bond. This corroborates the observation that the cyclic CEP-1 structure was fully visible in the crystal structures, while only one-half of the sequences from CII-C-13 and CII-C-48 were visualized.
In summary, we have provided a molecular explanation for the most significant antibody-antigen interactions associated with the development of RA. These findings may explain the promiscuous and specific recognition of citrullinated peptides by ACPAs.
